

Article

The circulating transcriptome as a source of biomarkers for melanoma

Carla Solé¹, Daniela Tramonti², Maike Schamm^{1,3}, Ibai Goicoechea¹, María Armesto¹,
Luiza I. Hernandez¹, Lorea Manterola¹, Marta Fernandez-Mercado¹, Karmele Mujika⁴,
Anna Tuneu⁵, Ane Jaka⁵, Maitena Tellaetxe¹, Marc R. Friedländer^{6,7,8,9,10}, Xavier Estivill^{6,7,8,9},
Paolo Piazza^{11,12}, Pablo L. Ortiz-Romero^{13,14}, Mark R. Middleton² and Charles H. Lawrie^{1,15,16*}

- ¹ Molecular Oncology group, Biodonostia Research Institute, San Sebastián, Spain
carla.sole@biodonostia.org (C.S.); ibai.goicoechea@biodonostia.org (I.G.); maria.armesto@biodonostia.org (M.A.); luiza.hernandez@liu.se (L.H.); lorea.manterola@biodonostia.org (L.M.);
marta.fernandez@biodonostia.org (M.F.-M); maitena.tellaetxe@biodonostia.org (M.T.)
- ² Department of Oncology, University of Oxford, Oxford, UK
mark.middleton@oncology.ox.ac.uk (M.M.); dtramonti@hotmail.com (D.T.)
- ³ Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany
maiike.schramm@stud.uni-heidelberg.de (M.S.)
- ⁴ Onkologikoa- Oncology Institute Gipuzkoa, Gipuzkoa, Spain
kmujika@onkologikoa.org (K.M.)
- ⁵ Department of Dermatology, Hospital Universitario de Donostia, San Sebastian, Spain
annadonosti@gmail.com (A.T.); iratzia@hotmail.com (A.J.)
- ⁶ Genomics and Disease group, Centre for Genomic Regulation (CRG), Barcelona Spain
xavier.estivill@crge.es (X.E.)
- ⁷ Universitat Pompeu Fabra (UPF), Barcelona Spain
- ⁸ Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
- ⁹ Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- ¹⁰ Science for Life Laboratory, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
marc.friedlander@scilifelab.se (M.F.)
- ¹¹ Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- ¹² Imperial BRC Genomics Facility, Imperial College London, London, UK
p.piazza@imperial.ac.uk (P.P.)
- ¹³ Department of Dermatology, 12 de Octubre Hospital, Madrid, Spain
- ¹⁴ Medical School, Universidad Complutense, Institute i+12, CIBERONC, Madrid, Spain
pablo.ortiz@salud.madrid.org (P.L.O.)
- ¹⁵ Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- ¹⁶ IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
- * Correspondence: Charles Lawrie, Biodonostia Research Institute, Paseo Doctor Begiristain, San Sebastián, 20014, Spain. E-mail: charles.lawrie@biodonostia.org (C.H.L.)

Abstract: The circulating transcriptome is a valuable source of cancer biomarkers, which with the exception of miRNAs, remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients of healthy individuals, we used next generation sequencing (NGS) and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed ($P < 0.05$). Levels of *miR-134-5p* and *miR-320a-3p* were significantly down-regulated ($P < 0.001$) in melanoma samples ($n = 96$) compared to healthy controls ($n = 28$). Differentially expressed protein-encoding mRNA, 5'-fragments, were enriched for the angiopoietin, PAK and EIF2 pathways. Levels of *ATM1*, *AMFR*, *SOS1* and *CD109* gene fragments were up-regulated ($P < 0.001$) in melanoma samples ($n = 144$) compared to healthy controls ($n = 41$) (AUC = 0.825). Over 40% of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of *RNY3P1*, *RNY4P1* and *RNY4P25* were significantly higher

in patients with stage 0 disease, than either healthy controls or more advanced stage disease ($P<0.001$). In conclusion, we have identified a number of novel RNA biomarkers, which most importantly we validated in multi-centre retrospective and prospective cohorts suggesting potential diagnostic use of these RNA species.

Keywords: melanoma, plasma, liquid biopsy, miRNA, mRNA, biomarker, YRNA, RNA species.

1. Introduction

Although malignant melanoma accounts for ~4% of skin cancer cases, it accounts for ~75% of all associated mortalities. In the US alone, it is estimated there were 87,000 new cases and nearly 10,000 deaths due to melanoma in 2017 [1]. Furthermore, the incidence of melanoma has been increasing at faster rate than any other cancer type, having doubled since 1973 [2]. The clinical case for early diagnosis of melanoma is compelling, as if detected early enough (stage I) 5-year survival is >95% whereas in advanced melanoma (stage IV) just 10-20% [3].

Non-invasive diagnostics, or liquid biopsies, represent a major advance towards earlier diagnosis and disease monitoring of cancer patients, including those with melanoma. As a consequence, there has been a great deal of interest in recent years in the potential of circulating nucleic acids, and in particular circulating microRNAs (miRNAs) [4, 5]. In melanoma several studies have implemented circulating miRNA in metastasis and risk of recurrence [6, 7]. However, outside of miRNAs there has been little research on other cell-free (cf)RNA species in the circulating transcriptome. Part of the reason for this paucity of knowledge is the presence of high levels of RNase activity in blood, that typically results in fragmentation of longer RNA species such as mRNA [8, 9]. This makes detection of these molecules particularly challenging. The advent of next-generation sequencing (NGS) technology however presents new opportunities for the field as sequences can be elucidated in a 'bottom-up' manner without the need of *a priori* probe sequence knowledge. We used next generation sequencing (NGS) to characterize and compare the circulating transcriptomes of plasma from melanoma patients with different stage disease, along with sex/age matched healthy individuals in order to identify novel biomarkers for this cancer.

We identified not only circulating miRNAs with biomarker potential, but also mRNA gene fragments and non-coding YRNAs. YRNAs (Ro-associated Y) are poorly characterized non-coding RNAs, that were initially identified in the blood of rheumatic autoimmune disease patients [10]. They are a family based around four highly conserved sequences (*RNY1*, *RNY3*, *RNY3*, *RNY5*) involved in Ro60 inhibition, DNA replication and quality control of non-coding RNAs [11-13]. Our possible biomarkers were validated in an independent cohort of 327 plasma samples from melanoma patients collected retrospectively and prospectively. This study provides evidence that the largely unexplored circulating transcriptome could provide a valuable source of liquid biopsy biomarkers for melanoma in particular and cancer in general.

2. Results

2.1. Sequencing the circulating transcriptome of melanoma patients

We optimized the library construction by comparing several protocols including different ribodepletion methodologies using plasma from healthy controls in a pilot study, before settling on

the protocol described above (data not shown). Using this protocol, we sequenced cfRNA derived from plasma of melanoma patients, along with age/sex matched controls (Table 1).

Due to the low quantity of cfRNA in plasma, we decided to pool plasma samples according to clinical stage as depicted in Table 1. For each pooled sample 40-50 million reads were obtained, with an average Phred score of 37.9 (Supplementary Table S1). Between 50-55% of reads were mapped to the human genome (hg19), and approximately half of these sequences were considered small RNA (sRNA), representing sequences between 18-43 nt (Supplementary Table S1; Figure 1a). By far the largest category by frequency of reads was YRNAs, accounting for an average of 40.6% of reads (range 34-48%; Figure 1). Indeed, this category accounted for >95% of reads that composed the major peak, at 32 nt, seen in size profile of samples (typical example shown in Figure 1a).




Figure 1: RNaseq results from circulating transcriptome. (a) Typical length-frequency of obtained reads in library. Proportion of reads mapping to different categories of sRNA for (b) Control pool, (c) Stage 0 pool, (d) stage I/II pool, (e) stage III pool, (f) stage IV pool.

	Stage	n	Age (median)	Sex (M/F/(NK))
NGS cohort	Control	8	58	4/4
	Pool 0	5	76	3/2
	Pool I/II	8	63	4/4
	Pool III	8	68	3/5
	Pool IV	8	59	3/5
mRNA validation cohort	Control	41	54	18/23
	Stage 0	29	64	11/17/(1)
	Stage I/II	44	58	19/25
	Stage III/IV	71	57.5	32/37/(2)
miRNA validation cohort	Control	28	58	12/14/(2)
	Stage 0	29	51	6/19/(4)
	Stage I/II	33	60	10/14/(9)
	Stage III/IV	34	55	11/15/(8)
YRNA validation cohort	Control	22	57.5	11/11/
	Stage 0	20	51	11/5/(4)
	Stage I/II	17	48	9/8
	Stage III/IV	21	61	8/13
Total	-	426	58	175/221/(30)

Table 1: Summary of clinical details of patient cohorts used in study. NK: not known.

2.2. miRNA expression

We detected 442 different human miRNA sequences in the samples which accounted for between 1.38×10^5 and 3.14×10^5 reads per sample. The most abundant miRNAs were members of the *let-7* family that accounted for >70% of mapped miRNAs reads, followed by *miR-423* and *miR-320a-3p*. Eleven miRNAs were identified as being differentially expressed ($P < 0.05$, >50 reads per sample; Table 2). We measured levels of the four most differentially expressed miRNAs (*miR-134-5p* and *miR-320a-3p*, *miR-21-5p* and *miR-92b-3p*) by qRT-PCR plasma samples in 28 healthy controls and 96 melanoma patients (Table 1). We were unable to detect *miR-21-5p* and *miR-92b-3p* (data not shown).

miRNA	Cont.	Stage 0	Stage I/II	Stage III	Stage IV	P-value
<i>miR-134-5p</i>	7474	7290	2293	4200	4876	0.0158
<i>miR-320a-3p</i>	117411	76952	56705	86933	74154	0.0181
<i>miR-21-5p</i>	356	405	368	782	469	0.0183
<i>miR-92b-3p</i>	14	14	20	25	51	0.0232
<i>miR-98-5p</i>	9850	12999	9124	14243	13627	0.0232
<i>miR-16-3p</i>	21	29	49	39	53	0.0277
<i>Let-7b</i>	385	507	326	267	396	0.0286

<i>miR-1827</i>	58	28	7	7	11	0.0375
<i>miR-1180</i>	107	145	49	45	42	0.0392
<i>miR-628</i>	499	667	375	502	407	0.0496
<i>miR-486</i>	4581.23	6014.45	1501.33	2704.89	1879.67	0.0497

Table 2. Differentially expressed miRNAs (P<0.05). Counts were normalized per million reads. miRNAs validated are depicted in bold.

Consistent with the NGS data, we found that *miR-134-5p* and *miR-320a-3p* were significantly down-regulated in patients compared to controls (Figure 2a-b). Levels of these miRNAs were lower in stage 0 patients than in healthy controls, and even lower in stage I/II patients (P<0.05). ROC analysis gave AUC values of 0.798 (*miR-320a-3p*) and 0.788 (*miR-134-5p*) with a higher sensitivity (90%) for *miR-320a-3p* and higher specificity for *miR-134-5p* (96%) (Figure 2c-d and Table 3).




Figure 2. Expression levels of miRNAs measured by qRT-PCR in independent validation cohorts. (a and b) Levels of *miR-320a* and *miR-134* were measured in a cohort of 124 plasma samples (28 controls and 96 melanoma patients). (c and d) ROC analysis of miRNA probe expression levels as diagnostic biomarker (i.e. control vs. melanoma patients).

Probe	AUC	Sensitivity	Specificity	95% CI	0*	I/II*	III/IV*
<i>miR-320a-3p</i>	0.798	90%	61%	0.712-0.869	0.751	0.870	0.828
<i>miR-134-5p</i>	0.788	55%	96%	0.704-0.858	0.680	0.868	0.811
ATM	0.767	61%	72%	0.697-0.829	0.769	0.734	0.715

AMFR	0.748	52%	92%	0.676-0.812	0.822	0.709	0.641 ¹⁷⁸
CD109	0.753	54%	90%	0.680-0.816	0.816	0.706	0.702 ¹⁷⁹
SOS1	0.772	48%	95%	0.699-0.835	0.796	0.694	0.693
Panel	0.825	75%	92%	-	-	-	0.180


Table 3. ROC analysis values of expression levels of differentially expressed miRNAs and gene fragments.
*AUC values of different stage vs. control sample. Panel is a combination of ATM, AMFR and SOS1

2.3. mRNA fragment expression

Because mRNA is degraded by RNase activity in the blood into fragments with average size of 200 bases [14], rather than mapping reads to whole genes or exons, we mapped them to short annotated probe sets (<500 bases). There were 3672 different probe sets (median length of 244 nt) with greater than 25 reads per probe set mapping to 13,641 different transcripts. For each probe set we analysed their relative position within the respective transcripts as a percentage of the entire transcript length. By far the largest proportion (5350/13641 (39%)) of probe sets mapped to the first decile (10%) (i.e. 5'-end) of the transcript, compared to an average of 6% for the other nine deciles of the transcript length (Figure 3a).

Seventy of the probe sets were identified as being differentially expressed between samples (P<0.05; Table A1). We designed custom Taqman probes to detect fragments from the five most differentially expressed probe sets (i.e. corresponding to ATM, ARHGAP, AMFR, CD109, and SOS1 genes) (Supplementary Table S2; Figure S1). We were unable to design a specific probe for the ARHGAP probe set due to presence of high level of repetitive sequences. None of the mRNAs validated are predicted targets of miRNAs studied (i.e. miR-134-5p and miR-320a) using the predictive algorithms TargetScan and miRDB (data not shown). The four probe sets were measured by qRT-PCR in 41 control and 144 melanoma patient samples (Table 1).

Levels of ATM, AMFR, CD109, and SOS1 were all significantly higher (P<0.001) in plasma samples from either stage 0, stage I/II or stage III/IV melanoma patients than in healthy controls (Figure 3b-e, respectively) consistent with the NGS data (Table A1). Surprisingly, levels of AMFR and CD109 were higher in plasma from stage 0 patients than samples with more advanced disease. We carried out ROC analysis to determine the diagnostic ability of the mRNA fragments (Table 3; Figure 3f-i), and to discriminate between different disease stage (Table 3; Supplementary Figure S2a-d). We looked at combinations of these biomarkers using the PanelomiX ROC comparison algorithm [15]. A combination of ATM, SOS1 and AMFR with cut-off values of any one of the three of 2.13, 2.96 and 2.26 respectively, gave the best diagnostic accuracy (AUC=0.825) (Table 3, Figure 3j).



210

211 **Figure 3.** Expression levels of mRNA fragments measured by qRT-PCR in independent validation cohorts. (a)
212 Proportions of probe sets containing at least 25 reads (>500 bases in length) relative to their position (5' to
213 3'direction) along the respective transcript. (b-e) Levels of *ATM*, *AMFR*, *CD109* and *SOS1* probes were
214 measured in a cohort of 185 plasma samples (41 controls and 144 melanoma patients). Levels are shown relative
215 to the mean expression of the control sample cohort (i.e. $2^{-\Delta\Delta Ct}$). (f-i) ROC analysis of mRNA probe
216 expression levels as diagnostic biomarker (i.e. control vs. melanoma patient). (j) Panel (*ATM*, *AMFR* and *SOS1*)
217 performance shown with black line and for comparison *SOS1* is shown as a gray line.

2.4. YRNA expression

As nearly half of all mapped sRNA reads were identified as YRNA sequences (Figure 1), we examined this class of non-coding RNAs further. There were 322 different YRNA and YRNA-associated sequences identified in our samples, consisting of three YRNA sequences (RNY1, RNY3 and RNY4) representing an average of 26.1% of reads, 30 YRNA pseudogenes representing an average of 48.4% of reads, 69 7SK sequences (average 0.05% of reads), and 194 Rfam predicted YRNA sequences representing an average of 25.5% of reads (Supplementary Table S3). The vast majority of reads were represented by RNY4 and RNY4P sequences accounting for >98% of their respective YRNA class (Figure 4a).




Figure 4. YRNA expression in plasma samples. (a) Mean proportions of different YRNA species in NGS cohort plasma samples. Levels of (b) *RNY3P1*, (c) *RNY4P1* and (d) *RNY4P25* measured by ddPCR in an independent validation cohort of 80 plasma samples (22 controls and 58 melanoma patients). Values are shown as absolute copies per μL.

We compared the expression of YRNAs between low stage disease (i.e. stage 0 and I/II) and high-grade disease (i.e stage III and IV) and identified five differentially expressed YRNA fragments ($P < 0.05$; Table 4). We designed custom Taqman probes to measure three of these YRNAs (*RNY3P1*, *RNY4P1* and *RNY4P25*), selected on the basis of fold-change and read count. We measured levels of the YRNAs in a validation cohort of 80 samples (22 controls and 58 melanoma patients, Table 1).

Levels of all three YRNAs were significantly higher in stage 0 samples than control samples or stage I/II samples (Figure 4b-d).

	Stage 0/I/II	Stage III/IV	Fold Change	P-value
<i>RNY4P18</i>	85	193	2.2	0.00033
<i>RNY3P1</i>	86	210	2.4	0.00063
<i>RNY4P6</i>	12,442	24,473	1.9	0.00072
<i>RNY4P1</i>	68	146	2.1	0.00090
<i>RNY4P25</i>	180	317	1.7	0.0032

Table 4. Differentially expressed YRNAs (P<0.05). Counts were normalized per million reads. YRNAs validated are depicted in bold.

3. Discussion

The presence and relative stability of cfRNA in biological fluids has led to a great deal of interest in their use as ‘liquid biopsies’ for disease, in particular for cancer. However, with the exception of miRNAs, the circulating transcriptome remains largely unexplored. Whilst NGS offers researchers the ability to elucidate the circulating transcriptome in its entirety, and therefore identify novel biomarkers of disease, the application of RNAseq to biofluids such as plasma poses many challenges, not least of all the low quantity and low quality of RNA present in these samples. As a consequence, studies to date have focused on the technical optimization of these techniques [10][11, 12]. However, to date very few studies have sought to assess the potential usefulness of their findings through validation in independent cohorts.

In order to fully explore the complexity and biomarker potential of the melanoma circulating transcriptome we pooled samples to maximize the starting quantity of cfRNA. As a result we were able to obtain 40-50 million reads per pooled sample, an order of magnitude higher than comparable studies [16, 17]. In contrast to exosomal cfRNA [16], we found that miRNAs only represented a minor component (<3%) of the whole plasma circulating transcriptome, levels similar to other plasma NGS studies [17-19]. We identified 442 different miRNAs in our samples, somewhat higher than that reported in comparable studies [20, 21], probably as a result of the pooled design and the higher quantity of RNA that we used. Consistent with other studies we found that *let-7b*, *miR-423* and *miR-320a-3p* were the most highly expressed miRNAs in our plasma samples [17]. We identified eleven miRNAs that were differentially expressed between healthy controls and the different clinical stages of melanoma (Table 2). This included miR-21 that has previously been shown to be upregulated in melanoma plasma samples [16], and miR-92b and miR-628, both of which are more highly expressed in plasma from monosomy 3 uveal melanoma patients [17].

Based on our sequencing results, we measured the expression of *miR-320a-3p* and *miR-134-5p*, the two miRNAs most differentially expressed between samples, in a validation cohort of 96 melanoma patients and 28 controls. Both miRNAs were significantly down-regulated (P<0.0001) in plasma from all stages of melanoma patients, when compared to samples from healthy controls. *MiR-320a* has also been found to be down-regulated in melanoma tumour cells when compared to healthy skin samples [24]. Furthermore, this miRNA was shown to function as an inhibitor of cell proliferation. The down-regulation of *miR-320a* has been observed in the blood of several cancers including colorectal cancer [25], gastric cancer [26], and retinoblastoma [27]. Moreover, *miR-320a* is up-regulated in melanoma cells after treatment with Bevacizumab or Rapamycin + Bevacizumab

[28]. *miR-134* has been characterized as a tumor suppressor, acting to regulate proliferation, apoptosis, and invasion and migration, in a wide range of cancer types including melanoma [31, 32]. ROC analysis of miRNA expression gave AUC values of 0.798 and 0.788 respectively. *miR-320a* had a sensitivity of 90%, whereas *miR-134* had a specificity of 96%, suggesting a combination of these two miRNAs could be useful biomarkers for melanoma.

Even though circulating extracellular mRNA was first detected in 1999 (in melanoma) [33], as the vast majority of circulating mRNA is degraded by blood RNase activity [34], this potential source of biomarkers has largely been overlooked even though mRNA fragments can represent up to 75% of total cfRNA [10]. In our study just over 5% of mapped reads corresponded to protein-encoding mRNA fragments. We detected 3672 probes (<500 bases in length) that had at least 25 mapped reads in our samples. Nearly 40% of the probe mRNA fragment mapped to the 5'-terminus (i.e. first 10%) of their respective gene transcripts, probably reflecting the 3' to 5' cleavage activity of RNase A, the major RNase species in blood [27]. We did not notice a corresponding shift in the length profile between healthy and melanoma patient samples (data not shown)

Pathway analysis of the genes corresponding to differentially-expressed mRNA fragments showed significant enrichment in the angiopoietin, PAK and EIF2 pathways. It has been previously reported that circulating levels of Angiopoietin-2 (Ang-2) protein in melanoma patient sera closely correlates with disease progression [28]. Similarly, amplification of the PAK (p21-activated kinase) pathway is characteristic of BRAF-wild type melanoma [29], whilst in BRAF-mutant melanoma responsible for resistance to MAPK-inhibitor treatment [30]. Interestingly, both *SOS1* and *ATM1*, which were the third and fourth most differentially expressed probe sets in our analysis, form part of the angiopoietin, PAK and EIF2 pathways. We measured levels of *SOS1*, *ATM1*, *CD109* and *AMFR* mRNA fragments in plasma samples from 144 melanoma patients and 41 healthy controls. With the exception of *CD109*, these mRNA fragments mapped to regions corresponding to the 5'-terminus of the reference gene transcript and included the initiation codon. Consistent with the NGS data (Table A1), levels of all these mRNA fragments were up-regulated in melanoma patient samples compared to samples from healthy controls. Particularly intriguing was the up-regulation of *CD109* and *AMFR* in stage 0 samples compared to samples from more advanced stage melanoma suggesting these mRNA fragments could be used for early diagnosis of melanoma, although we do not have data on how many of these patients went on to develop advanced disease. (Figure 3b-e). *CD109* has been identified as an important regulator of the Epithelial-mesenchymal transition (EMT pathway), and also found to be down-regulated in more advanced stage hepatocellular carcinoma [36]. The product of the *AMFR* gene, gp78, also regulates of EMT, and increasing levels of *AMFR* are associated with metastatic melanoma [37, 38]. Intriguingly, *CD109* is a predicted target of *miR-134* by the Targetscan algorithm; we are currently carrying out experiments to confirm this. *ATM1* is serine/threonine kinase induced by DNA damage and associated with risk in many cancer types [39]. *SOS1* is a guanine nucleotide exchange factor for RAS proteins frequently mutated in melanoma [40]. Interestingly all four of these gene fragments were more highly expressed not only in advanced stage disease but also stage 0 disease, indeed levels of *CD109* and *AMFR* were higher in plasma from stage 0 disease than more advanced stage disease, suggests that these biomarkers maybe non-tumoral in origin. Consistent with this hypothesis, the release of *CD109* by bone marrow mesenchymal stem cells has recently been shown to attenuate EMT in skin squamous cell carcinoma [41], and *AMFR* plays an important role in regulation of the anti-cancer immune STING pathway [42].

To test the potential diagnostic ability of these biomarkers we carried out ROC analysis, however the results from individual mRNA fragments were poor (AUC range 0.722 (*SOS1*) to 0.767 (*ATM1*). In contrast, a combination of *ATM1*, *SOS1* and *AMFR* resulted in an AUC value of 0.825 with a sensitivity of 75% and specificity of 92%. Although these findings need to be confirmed independently, this combination compares very favorably with existing sera markers such as LDH and S100B with reported sensitivities/specificities of 41.6/84.2% and 36.3/96.5%, respectively [43].

By far the largest class of circulating cfRNA that we identified in the samples, corresponded to YRNA sequences accounting for close to 50% of sRNA mapped reads. Remarkably, despite the prevalence of cfYRNAs in the blood, there is very little known about this class of ncRNA. YRNAs are short 80-110 nt ncRNAs that were first identified in the early 1980's as a RNA component of the soluble Ro60 ribonucleoprotein particle found in the blood of patients with autoimmune diseases [44]. The function of YRNAs is still poorly understood; they appear to be essential for DNA replication [45], and are up-regulated in cancers [46], presumably as a result of their association with apoptosis [47]. The first description of circulating cfYRNAs came in 2013 from Dhahbi et al who observed that 33% of mapped reads from sera of healthy individuals were YRNA sequences [48]. The same group later reported that YRNA accounts for 38% of cfRNA in sera from breast cancer patients [49], and subsequently, in the sera of head and neck squamous cell carcinoma patients [50]. More recently a study of 183 plasma samples from healthy individuals found that YRNAs accounted for 63% of cfRNA [51]. As far as we are aware, apart from a recent study that measured YRNAs in the sera of 30 renal carcinoma patients [52], this the first study to look at the biomarker potential of YRNAs in cancer patients. Interestingly, we found that levels of YRNAs were significantly higher in samples from patients with stage 0 disease, maybe pointing to increased levels of tumour-associated apoptosis [47] even despite the small tumour sizes compared to more advanced disease stages.

In summary, we have elucidated the circulating transcriptome of plasma samples from melanoma patients and found a number of novel RNA biomarker species that we validated independently using qRT-PCR and ddRT-PCR in combined retrospective and prospective cohorts, detected from only 1mL of serum. Whilst it is clear that further validation is required, this study provides strong evidence that the circulating transcriptome holds much promise as a source of liquid biopsies for melanoma that surely merits further exploration.

4. Materials and Methods

4.1. Patient cohorts

Patient plasma samples were collected both retrospectively (n=110) and prospectively (n=217). Retrospective samples were obtained from the John Radcliffe Hospital, Oxford (Oxford cohort; n=25), and the AVAST-M multi-center phase 3 clinical trial (AVAST-M cohort; n=85) [53]. Samples collected prospectively came either from the Hospital 12 de Octubre in Madrid (Madrid cohort; n=108), or the Onkologikoa Cancer Hospital and Donostia University Hospital of San Sebastián (San Sebastián cohort; n=109); a total of 327 melanoma patients. Samples were collected at the time of diagnosis and prior to any treatment. Plasma from age/sex matched healthy controls (n=99) were obtained from the Basque Biobank for Research O+EHUN. Plasma preparation was carried out within 1 hr of phlebotomy, with blood collected in EDTA-coated tubes followed by centrifugation for 1,000g for 15 min at 4°C.

With the exception of the 37 prospectively collected samples used for NGS (Table 1), only a limited volume (1-2 ml) of plasma was available for validation studies. Therefore, we divided samples into three separate validation cohorts; a miRNA cohort of 96 melanoma patients and 28 controls; a mRNA cohort of 144 melanoma patients and 41 controls; and a YRNA cohort of 58 melanoma patients and 22 controls. The clinical details of the patients used are summarized in Table 1, and details of individual cohorts are provided in Supplementary Tables S4-S7. Written informed consent was obtained from patients for the inclusion of their samples in this study and samples were collected in accordance with the Declaration of Helsinki and approved by local ethics committees (CEIC-Euskadi approval number PI2015024).

For the plasma samples used for NGS (5-8ml), cfRNA was purified using the plasma RNA purification kit from Norgen Biotek (Ontario, Canada), and for validation studies (1ml samples) using the miRCURY™ RNA Isolation Kit Biofluids (Exiqon).

4.2. Library construction and next-generation sequencing

The samples used for NGS were pooled according to disease stage as shown in Table 1. Ribosomal RNA (rRNA) was removed from total cfRNA using the Ribozero Magnetic Human/Mouse/Rat kit (Epicentre, #MRZH116), according to the low input protocol recommended by the manufacturer. Phosphatase and PNK treatments were carried out on the ribodepleted RNA, and Illumina small RNA adapters ligated. Libraries were amplified using 15 cycles of PCR of barcoded primers [54]. Sequencing was performed on an Illumina HiSeq 2500 as 50 PE in rapid mode.

4.3. Bioinformatic analysis

Sequencing reads were quality filtered using the fastx_artifacts_filter tool and ligation adapters removed using the AdRec.jar program (seqBuster suite of programs). Reads were mapped to the GRCh37 build of the human genome using the Bowtie 2.0 algorithm. A custom annotated probe set was built by combining probes from GENCODE version 8 [55], supplemented with rRNA and repeat annotations from RepeatMasker GRCh37, and snoRNA annotations from the UCSC table browser [56]. MiRNA expression was calculated using the miraligner algorithm from the seqBuster suite, and YRNA expression calculated using the HTseq-count algorithm. Differential expression analysis was carried out using the DESeq bioconductor package [57].

4.4. qRT-PCR (mRNA and miRNA) and ddPCR(yRNAs)

mRNA was reverse transcribed (RT) using random primers with the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems following the manufacturers' protocol with DNase treatment. Due to the difficulty in quantifying cfRNA reliably we used fixed volumes in reactions [4, 58]. For gene fragments, we designed custom Taqman probes using the Custom TaqMan® Assay Design Tool from Applied Biosystems using the sequences corresponding to the respective probe sets (Supplementary Table S2 and Figure S1). 18S rRNA was used as a reference gene for mRNA analysis as previously described [59].

For miRNA detection, we used the Megaplex RT Primers Human Pool A v2.1 for RT, and specific Taqman probes as described in the text. As the problems of defining suitable reference genes for miRNA detection in plasma are well documented [4], we measured levels of three previously described reference miRNAs (miR-24, miR-16 and miR-191) [60, 61], in a cohort of 63 samples (control/stage 0 (n=22), stage I/II (n=26), stage III/IV (n=15)). Using the NormFinder algorithm we identified miR-24 and miR-191 as the most stable combination of reference genes in our samples (Supplementary Figure S3).

Custom primers and Taqman probes for Y3P1, Y4P1 and Y4P25 were designed using the Custom Taqman® Small RNA Assay Design Tool from Applied Biosystems. ddPCR was performed using QX200™ Droplet Digital™ PCR system (Bio Rad) following the manufacturers' protocol. Data analysis was performed by QuantaSoft analysis software from Bio-Rad. Expression levels were compared using Mann-Whitney independent t-test (Graphpad Prism v. 5.0, La Jolla, CA, USA).

ROC analysis and comparisons were carried out using the method of DeLong et al as implemented in MedCalc v. 14.8 software [62].

5. Conclusions

We have carried out a comprehensive no-biased elucidation of the circulating transcriptome of melanoma patients and identified a number of promising candidate biomarker RNA species, not only miRNAs. These candidates were validated in independent cohorts by ourselves, however it is clear that further studies should be carried out by independent research groups in order to strengthen our findings and facilitate the translation of this knowledge into the clinic.

What is obvious is that many virtually unexplored classes of the circulating transcriptome are yet to be fully assessed for their ability to serve as useful cancer biomarkers. As a consequence, whilst the discovery of circulating miRNAs represented an important event in the history of the liquid biopsy field, it is clear that there is much that we have still to explore.

Supplementary Materials: Figure S1: Mapping positions (GRCh37) of selected gene fragment probe sets used to design Taqman probes. Figure S2: Variation of Ct values in levels of miRNA reference genes in selected cohort measured by qRT-PCR. Figure S3: ROC analysis of mRNA expression in different melanoma stage cohorts. Table S1: Summary of NGS results from pooled RNA samples. Table S2: Characteristics of selected differentially protein-encoding gene fragment probe sets. Table S3: YRNA reads from NGS. Table S4: Clinical details of patients used for NGS cohort. Table S5: Clinical details of patients used in mRNA validation cohort. Table S6: Clinical details of patients used in miRNA validation cohort. Table S7: Clinical details of patients used in yRNA validation cohort.

Author Contributions: conceptualization, C.S.; D.T. and CHL.; methodology, C.S.; M.S.; I.G.; M.T. and CHL.; validation, C.S.; M.A.; L.H.; L.M.; M.S.; formal analysis, M.R.F.; M.F.M.; P.P.; X.E.; I.G.; M.T. and CHL.; resources, D.T.; K.M.; A.T.; A.J.; P.L.O.; M.R.M.; data curation, P.L.O.; M.T.; M.R.M.; writing—original draft preparation, C.S. and CHL.; writing—review and editing, C.S. and C.H.L.

Funding: CHL and his research is supported by grants from the IKERBASQUE foundation for science, the Starmer-Smith memorial fund, Ministerio de Economía y Competitividad (MINECO) of the Spanish Central Government and FEDER funds (PI12/00663, PIE13/00048, DTS14/00109, PI15/00275), Departamento de Desarrollo Económico y Competitividad y Departamento de Sanidad of the Basque government, Asociación Española Contra el Cancer (AECC), and the Diputación Foral de Guipuzcoa (DFG). MRF was supported by EMBO Long-Term fellowship ALTF 225–2011. M.F.-M also acknowledges support from MINECO (PI16/00159), DFG and AECC.

Acknowledgments: We thank the Basque Biobank for Research O+EHUN for the plasma samples.

Conflicts of Interest: The authors declare that there are no conflicts of interest.

Appendix A

<i>Gene</i>	<i>Chromosome position*</i>	<i>Length</i>	<i>P-value</i>	<i>Cont.</i>	<i>St. 0</i>	<i>St.I/II</i>	<i>St.III</i>	<i>St.IV</i>
CD109	6:74446106-74446231	125	0.00103	39	102	126	207	318
ARHGAP	4:148744047-148744108	61	0.0018	45	9	11	10	8
SOS1	2:39237725-39237844	119	0.00196	23	16	130	121	139
ATM	11:108099905-108100050	145	0.00316	5	20	8	7	105
AMFR	16:56396751-56396855	104	0.00329	11	32	59	59	121
KCNIP3	2:95976103-95976544	441	0.00362	1	14	22	16	28
POLE	12:133248801-133248908	107	0.00456	0	36	11	12	72
KLHL7	7:23213634-23214040	406	0.00479	0	6	10	8	40
ZMYM4	1:35824626-35825047	421	0.00547	54	23	25	27	22
GTDC1	2:144966170-144966371	211	0.00632	58	15	16	21	14
RFWD2	1:176132951-176133027	76	0.00651	27	11	10	13	12
ARHGAP10	4:148778704-148779039	335	0.00672	31	10	13	11	13
RHBDD1	2:227778924-227779353	429	0.00774	71	63	39	33	28
HNRNPM	19:8527413-8527473	60	0.00798	42	15	20	17	19
DYNC2H1	11:102988360-102988592	232	0.00835	0	15	17	15	60
ITIH5	10: 7613668-7614061	393	0.00885	0	11	12	6	32
TNFA1P2	14:103592664-103593029	365	0.00974	29	28	84	76	60
SLC40A1	2:190430080-190430325	245	0.00996	21	20	31	28	34
SETDB1	1:150902443-150902932	489	0.0106	1	20	23	17	60
IGF2BP3	7: 23385559-23385780	221	0.0118	27	27	11	14	15
DENND3	8:142152302-142153707	205	0.0118	0	13	32	4	3
GAK	4:866054-866461	407	0.014	0	11	16	10	40
ARHGEF12	11: 120278447-120282546	99	0.015	72	78	52	39	44
HINT3	6: 126298790-126301387	497	0.0157	76	66	8	19	11
HTR1E	6: 87647124-87647541	417	0.0158	41	95	106	75	92
UXS1	2:106780123-106780166	43	0.0171	60	5	5	6	2
MPP2	17: 41983448-41983519	71	0.0173	11	9	22	29	18
NAIP	5: 70308275-70308745	470	0.0183	0	10	41	5	2
SNCA	4:90757894-90758379	485	0.0185	73	44	49	49	41
TRAPPC9	8:140922366-140922544	178	0.0185	28	68	76	53	59
PISD	22:32034352-32034488	136	0.0189	225	533	600	413	557
SERPINB1	6: 2836090-2836257	233	0.0193	29	14	10	14	13
GRN	17:42429383-42429616	167	0.0193	0	7	25	2	2
EIF4G3	1: 21231376-21231464	88	0.0195	49	45	38	33	33
ILK	11: 6624961-6625456	495	0.0196	28	49	46	59	47
C14ORF38	14:60031765-60031993	240	0.0197	26	7	11	9	7
PSAP	10:73578788-73579028	228	0.0197	1	13	27	44	13
TMEM104	17: 72835466-72835918	452	0.0212	46	35	11	19	16

TAOK1	17:27849298-27849537	239	0.0217	42	9	12	6	11
SIAE	11:124506788-124507098	310	0.022	26	22	6	12	7
CDK5RAP2	9:123165584-123165940	356	0.0229	4347	9583	12031	8114	9164
TPT1	13:45911208-45911614	406	0.0239	55	31	38	34	30
SSH3	11:67070919-67071162	243	0.024	236	73	71	46	40
SSB	2:170667368-170667554	186	0.0247	0	8	28	7	1
ZNF430	19:21216892-21216990	98	0.025	48	11	17	12	8
HBA2	16:222846-223262	494	0.0266	266	141	135	177	134
ZFPM2	8:106456508-106456609	101	0.0304	70	41	43	49	49
RBM5	3:50145665-50145738	73	0.0308	60	19	16	28	16
ITGB1	10:33218750-33218972	222	0.0312	80	37	29	45	32
ZCCHC17	1:31821676-31821821	145	0.0329	15	17	20	23	26
PRKG2	4:82136085-82136218	133	0.0332	40	49	20	29	26
IFI6	1:27992572-27992986	414	0.0341	0	0	46	1	2
MX2	21:42774561-42776800	458	0.0363	0	0	31	1	1
PSMD2	3:184020467-184020611	144	0.0366	0	2	12	28	1
HERC6	4:89363186-89364063	477	0.0376	0	3	54	4	1
PPBP	4:74853673-74853914	241	0.0387	685	259	301	403	260
PKN2	1:89206671-89206971	300	0.0389	66	27	27	22	15
TNIP1	5:150415143-150415268	125	0.039	7	5	36	16	14
ARGLU1	13:107209096-107210043	347	0.0396	0	11	42	5	6
LRRN2	1:204654448-204654861	413	0.0399	13	43	29	25	32
ACACB	12:109625804-109625967	163	0.0401	19	46	43	30	40
EIF5B	2:99980108-99980325	217	0.0415	39	14	22	18	15
FRA10AC1	10:95441237-95441355	118	0.0419	33	6	6	5	2
RASA1	5:86627165-86627317	152	0.0437	35	10	15	17	16
CHD9	16:53301839-53302038	199	0.0441	41	10	11	20	13
TPM1	15:63351762-63351879	117	0.0443	38	12	18	19	12
ACVR2	2:148657313-148657467	154	0.0462	26	21	16	10	14
MCTP1	5:94224580-94224677	250	0.0475	6	12	20	19	25
HOXC6	12:54404873-54407570	97	0.0481	26	62	71	45	49
ATF4	22:39916183-39917676	267	0.0487	26	28	18	18	18

Table A1. Differentially expressed protein-encoding probe sets ($P < 0.05$). Gene names and coordinates are given. Counts were normalized per million reads. mRNAs validated are depicted in bold.

482

483 **References**

- 484 1. Siegel R.L.; Miller, K.D., et al. Cancer Statistics, 2017. *CA Cancer J Clin* **2017**, *67*(1), 7-30. DOI:
485 10.3322/caac.21387
- 486 2. Weinstock M.A. Epidemiology, etiology, and control of melanoma. *Med Health R I* **2001**, *84*(7),
487 234-6.
- 488 3. Forsea A.M.; Del Marmol, V., et al. Melanoma incidence and mortality in Europe: new
489 estimates, persistent disparities. *British Journal of Dermatology* **2012**, *167*(5), 1124-30. DOI:
490 10.1111/j.1365-2133.2012.11125.x
- 491 4. Fernandez-Mercado M.; Manterola, L., et al. The circulating transcriptome as a source of
492 non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in
493 body fluids. *J Cell Mol Med* **2015**, *19*(10), 2307-23. DOI: 10.1111/jcmm.12625
- 494 5. Lawrie C.H.; Gal, S., et al. Detection of elevated levels of tumour-associated microRNAs in
495 serum of patients with diffuse large B-cell lymphoma. *Br J Haematol* **2008**, *141*(5), 672-5. DOI:
496 10.1111/j.1365-2141.2008.07077.x
- 497 6. Shiiyama R.; Fukushima, S., et al. Sensitive detection of melanoma metastasis using circulating
498 microRNA expression profiles. *Melanoma Res* **2013**, *23*(5), 366-72. DOI:
499 10.1097/CMR.0b013e328363e485
- 500 7. Friedman E.B.; Shang, S., et al. Serum microRNAs as biomarkers for recurrence in melanoma. *J*
501 *Transl Med* **2012**, *10*(155). DOI: 10.1186/1479-5876-10-155
- 502 8. Savelyeva A.V.; Kuligina, E.V., et al. Variety of RNAs in Peripheral Blood Cells, Plasma, and
503 Plasma Fractions. *Biomed Res Int* **2017**, *2017*(7404912). DOI: 10.1155/2017/7404912
- 504 9. Wong B.C. and Lo, Y.M. Plasma RNA integrity analysis: methodology and validation. *Ann N Y*
505 *Acad Sci* **2006**, *1075*(174-8). DOI: 10.1196/annals.1368.023
- 506 10. Pruijn G.J.; Wingens, P.A., et al. Ro RNP associated Y RNAs are highly conserved among
507 mammals. *Biochim Biophys Acta* **1993**, *1216*(3), 395-401.
- 508 11. Stein A.J.; Fuchs, G., et al. Structural insights into RNA quality control: the Ro autoantigen
509 binds misfolded RNAs via its central cavity. *Cell* **2005**, *121*(4), 529-539. DOI:
510 10.1016/j.cell.2005.03.009
- 511 12. Christov C.P.; Gardiner, T.J., et al. Functional requirement of noncoding Y RNAs for human
512 chromosomal DNA replication. *Mol Cell Biol* **2006**, *26*(18), 6993-7004. DOI:
513 10.1128/MCB.01060-06
- 514 13. Sim S. and Wolin, S.L. Emerging roles for the Ro 60-kDa autoantigen in noncoding RNA
515 metabolism. *Wiley Interdiscip Rev RNA* **2011**, *2*(5), 686-99. DOI: 10.1002/wrna.85
- 516 14. Savelyeva A.V.; Kuligina, E.V., et al. Variety of RNAs in Peripheral Blood Cells, Plasma, and
517 Plasma Fractions. *Biomed Res Int* **2017**, DOI: 10.1155/2017/7404912
- 518 15. Robin X; N., T., et al. PanelomiX: A threshold-based algorithm to create panels of biomarkers.
519 *Translational Proteomics* **2013**, *1*(1), 57-64.
- 520 16. Yuan T.; Huang, X., et al. Plasma extracellular RNA profiles in healthy and cancer patients. *Sci*
521 *Rep* **2016**, *6*(19413). DOI: 10.1038/srep19413
- 522 17. Danielson K.M.; Rubio, R., et al. High Throughput Sequencing of Extracellular RNA from
523 Human Plasma. *PLoS One* **2017**, *12*(1), e0164644. DOI: 10.1371/journal.pone.0164644
- 524 18. Qin Y.; Yao, J., et al. High-throughput sequencing of human plasma RNA by using
525 thermostable group II intron reverse transcriptases. *RNA* **2016**, *22*(1), 111-28. DOI:
526 10.1261/rna.054809.115
- 527 19. Guo Y.; Vickers, K., et al. Comprehensive evaluation of extracellular small RNA isolation
528 methods from serum in high throughput sequencing. *BMC Genomics* **2017**, *18*(1), 50. DOI:
529 10.1186/s12864-016-3470-z
- 530 20. Guo S.; Guo, W., et al. Serum miR-16: A Potential Biomarker for Predicting Melanoma
531 Prognosis. *J Invest Dermatol* **2016**, *136*(5), 985-93. DOI: 10.1016/j.jid.2015.12.041

21. Armand-Labit V.; Meyer, N., et al. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma. *Acta Derm Venereol* **2016**, *96*(1), 29-34. DOI: 10.2340/00015555-2156
22. Larrea E.; Sole, C., et al. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. *Int J Mol Sci* **2016**, *17*(5), DOI: 10.3390/ijms17050627
23. Glinge C.; Clauss, S., et al. Stability of Circulating Blood-Based MicroRNAs - Pre-Analytic Methodological Considerations. *PLoS One* **2017**, *12*(2), e0167969. DOI: 10.1371/journal.pone.0167969
24. Kozubek J.; Ma, Z., et al. In-depth characterization of microRNA transcriptome in melanoma. *PLoS One* **2013**, *8*(9), e72699. DOI: 10.1371/journal.pone.0072699
25. Fang Z.; Tang, J., et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. *J Exp Clin Cancer Res* **2015**, *34*(86). DOI: 10.1186/s13046-015-0198-6
26. Xu Q.; Dong, Q.G., et al. Expression of serum miR-20a-5p, let-7a, and miR-320a and their correlations with pepsinogen in atrophic gastritis and gastric cancer: a case-control study. *BMC Clin Pathol* **2013**, *13*(11). DOI: 10.1186/1472-6890-13-11
27. Liu S.S.; Wang, Y.S., et al. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. *Biomed Rep* **2014**, *2*(3), 424-428. DOI: 10.3892/br.2014.246
28. Wagenseller A.G.; Shada, A., et al. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. *J Transl Med* **2013**, *11*(218). DOI: 10.1186/1479-5876-11-218
29. Hummel R.; Wang, T., et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer. *Oncol Rep* **2011**, *26*(4), 1011-7. DOI: 10.3892/or.2011.1381
30. Wang W.L.; Chatterjee, N., et al. Effects of 1 α ,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. *Mol Cancer* **2011**, *10*(58). DOI: 10.1186/1476-4598-10-58
31. Pan J.Y.; Zhang, F., et al. miR-134: A Human Cancer Suppressor? *Mol Ther Nucleic Acids* **2017**, *6*(140-149). DOI: 10.1016/j.omtn.2016.11.003
32. Venkatesan N.; Kanwar, J., et al. Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations. *PLoS One* **2016**, *11*(1), e0146128. DOI: 10.1371/journal.pone.0146128
33. Kopreski M.S.; Benko, F.A., et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. *Clin Cancer Res* **1999**, *5*(8), 1961-5.
34. Reddi K.K. and Holland, J.F. Elevated serum ribonuclease in patients with pancreatic cancer. *Proc Natl Acad Sci U S A* **1976**, *73*(7), 2308-10.
35. Helfrich I.; Edler, L., et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. *Clin Cancer Res* **2009**, *15*(4), 1384-92. DOI: 10.1158/1078-0432.CCR-08-1615
36. Emori M.; Tsukahara, T., et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. *PLoS One* **2013**, *8*(12), e84187. DOI: 10.1371/journal.pone.0084187
37. Fang S.; Ferrone, M., et al. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. *Proc Natl Acad Sci U S A* **2001**, *98*(25), 14422-7. DOI: 10.1073/pnas.251401598
38. Timar J.; Raso, E., et al. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. *Clin Exp Metastasis* **2002**, *19*(3), 225-32.
39. Russell R.; Perkhof, L., et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. *Nat Commun* **2015**, *6*(7677). DOI: 10.1038/ncomms8677
40. Halaban R. and Krauthammer, M. RASopathy Gene Mutations in Melanoma. *J Invest Dermatol* **2016**, *136*(9), 1755-9. DOI: 10.1016/j.jid.2016.05.095

41. Zhou S.; Cecere, R., et al. CD109 released from human bone marrow mesenchymal stem cells attenuates TGF-beta-induced epithelial to mesenchymal transition and stemness of squamous cell carcinoma. *Oncotarget* **2017**, *8*(56), 95632-95647. DOI: 10.18632/oncotarget.21067
42. Wang Q.; Liu, X., et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity* **2014**, *41*(6), 919-33. DOI: 10.1016/j.immuni.2014.11.011
43. Garnier J.P.; Letellier, S., et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. *Eur J Cancer* **2007**, *43*(4), 816-21. DOI: 10.1016/j.ejca.2006.11.022
44. Hendrick J.P.; Wolin, S.L., et al. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. *Mol Cell Biol* **1981**, *1*(12), 1138-49.
45. Zhang A.T.; Langley, A.R., et al. Dynamic interaction of Y RNAs with chromatin and initiation proteins during human DNA replication. *J Cell Sci* **2011**, *124*(Pt 12), 2058-69. DOI: 10.1242/jcs.086561
46. Christov C.P.; Trivier, E., et al. Noncoding human Y RNAs are overexpressed in tumours and required for cell proliferation. *Br J Cancer* **2008**, *98*(5), 981-8. DOI: 10.1038/sj.bjc.6604254
47. Kowalski M.P. and Krude, T. Functional roles of non-coding Y RNAs. *Int J Biochem Cell Biol* **2015**, *66*(20-9). DOI: 10.1016/j.biocel.2015.07.003
48. Dhahbi J.M.; Spindler, S.R., et al. 5'-YRNA fragments derived by processing of transcripts from specific YRNA genes and pseudogenes are abundant in human serum and plasma. *Physiol Genomics* **2013**, *45*(21), 990-8. DOI: 10.1152/physiolgenomics.00129.2013
49. Dhahbi J.M.; Spindler, S.R., et al. Deep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer. *Biomark Cancer* **2014**, *6*(37-47). DOI: 10.4137/bic.s20764
50. Victoria Martinez B.; Dhahbi, J.M., et al. Circulating small non-coding RNA signature in head and neck squamous cell carcinoma. *Oncotarget* **2015**, *6*(22), 19246-63. DOI: 10.18632/oncotarget.4266
51. Yeri A.; Courtright, A., et al. Total Extracellular Small RNA Profiles from Plasma, Saliva, and Urine of Healthy Subjects. *Sci Rep* **2017**, *7*(44061). DOI: 10.1038/srep44061
52. Nientiedt M.; Schmidt, D., et al. YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. *Eur Urol Focus* **2016**, DOI: 10.1016/j.euf.2016.08.004
53. Corrie P.G.; Marshall, A., et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. *Lancet Oncol* **2014**, *15*(6), 620-30. DOI: 10.1016/S1470-2045(14)70110-X
54. Lamble S.; Batty, E., et al. Improved workflows for high throughput library preparation using the transposome-based Nextera system. *BMC Biotechnol* **2013**, *13*(104). DOI: 10.1186/1472-6750-13-104
55. Harrow J.; Frankish, A., et al. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Res* **2012**, *22*(9), 1760-74. DOI: 10.1101/gr.135350.111
56. Meyer L.R.; Zweig, A.S., et al. The UCSC Genome Browser database: extensions and updates 2013. *Nucleic Acids Res* **2013**, *41*(Database issue), D64-9. DOI: 10.1093/nar/gks1048
57. Anders S. and Huber, W. Differential expression analysis for sequence count data. *Genome Biol* **2010**, *11*(10), R106. DOI: 10.1186/gb-2010-11-10-r106
58. Moret I.; Sanchez-Izquierdo, D., et al. Assessing an improved protocol for plasma microRNA extraction. *PLoS One* **2013**, *8*(12), e82753. DOI: 10.1371/journal.pone.0082753
59. Lardizabal M.N.; Nocito, A.L., et al. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. *PLoS One* **2012**, *7*(5), e36323. DOI: 10.1371/journal.pone.0036323

634 60. Xiang M.; Zeng, Y., et al. U6 is not a suitable endogenous control for the quantification of
635 circulating microRNAs. *Biochem Biophys Res Commun* **2014**, *454*(1), 210-4. DOI:
636 10.1016/j.bbrc.2014.10.064
637 61. Marabita F.; de Candia, P., et al. Normalization of circulating microRNA expression data
638 obtained by quantitative real-time RT-PCR. *Brief Bioinform* **2016**, *17*(2), 204-12. DOI:
639 10.1093/bib/bbv056
640 62. DeLong E.R.; DeLong, D.M., et al. Comparing the areas under two or more correlated receiver
641 operating characteristic curves: a nonparametric approach. *Biometrics* **1988**, *44*(3), 837-45.